FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211250116> ?p ?o ?g. }

• W3211250116 endingPage "577" @default.
• W3211250116 startingPage "571" @default.
• W3211250116 abstract "Upadacitinib (UPA), a JAK inhibitor, is a new therapeutic option that allows patients with insufficient response to therapy with basic anti-inflammatory drugs (DMARDs) or genetically engineered biological drugs (GEBDs) to achieve the goals of therapy for rheumatoid arthritis (RA). Despite the availability of convincing data from international randomized clinical trials, there is insufficient information about the efficacy and safety profile of UPA, the quality of life of patients receiving the drug in real clinical practice. Aim of the study – to assess the efficacy and tolerability of the UPA drug at a dose of 15 mg/day in patients with rheumatoid arthritis with moderate and high disease activity and to assess their quality of life in real clinical practice. Materials and methods . The study included 41 patients with RA with insufficient effect of previous therapy with DMARDs or GEBDs, persisting moderate or high disease activity, who were initiated with UPA therapy in 7 rheumatological centers of the Russian Federation. To assess the activity of the disease, standard indices were used: DAS28- ESR, DAS28-CRP, SDAI, CDAI. Functional ability was assessed according to the HAQ questionnaire, quality of life – according to the EQ-5D questionnaire, the activity of the disease according to the patient’s opinion – according to the RAPID-3 index. The HADS scale was used to identify the states of depression, anxiety and emotional disorder. Results . During the first week of taking the drug, there was a marked decrease in pain from 60 to 30 mm on a visual analogue scale, which lasted until the third month of therapy. There was a statistically significant decrease in morning stiffness, the number of painful and swollen joints, health assessments by the doctor and patient, erythrocyte sedimentation rate and C-reactive protein (p≤0.001). A decrease in disease activity was also noted according to the dynamics of the activity indices DAS28, SDAI, CDAI (p<0.001). The goals of therapy (remission or low disease activity) by the 3rd month of therapy according to the combined indices of activity DAS28-ESR and DAS28-CRP reached 44.8 and 63.4% of patients, respectively, according to the SDAI index – 56.7%, according to the CDAI index – 25.9%. A pronounced improvement in joint function (70% improvement according to the criteria of the American College of Rheumatology) was noted by 33.3% of patients, population indicators of functional state (HAQ≤0.5) had 15.8% of patients. The difference in the HAQ index by the 3rd month of therapy compared to the indicator before treatment was –0.60 points. The quality of life, assessed by patients using the EQ-5D questionnaire, improved in 98.5% of patients, with a 70% improvement noted in more than a third of them (41.7%). The drug was well tolerated, no adverse reactions were registered by the 3rd month of therapy, all patients continued treatment. Conclusions . The first results of the use of UPA in RA patients with insufficient efficacy of previous therapy with DMARDs or GEBDs in real clinical practice indicate its efficacy and safety, an improvement in the functional state and quality of life of patients by the 12th week of the study." @default.
• W3211250116 created "2021-11-08" @default.
• W3211250116 creator A5002259667 @default.
• W3211250116 creator A5004963520 @default.
• W3211250116 creator A5005658823 @default.
• W3211250116 creator A5039980536 @default.
• W3211250116 creator A5041569976 @default.
• W3211250116 creator A5045228828 @default.
• W3211250116 creator A5063881785 @default.
• W3211250116 creator A5069106726 @default.
• W3211250116 creator A5074452337 @default.
• W3211250116 creator A5086694399 @default.
• W3211250116 creator A5089450492 @default.
• W3211250116 date "2021-10-31" @default.
• W3211250116 modified "2023-10-14" @default.
• W3211250116 title "The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”)" @default.
• W3211250116 cites W1987138256 @default.
• W3211250116 cites W2120393706 @default.
• W3211250116 cites W2166281097 @default.
• W3211250116 cites W2229566603 @default.
• W3211250116 cites W2257779930 @default.
• W3211250116 cites W2589710212 @default.
• W3211250116 cites W2740576013 @default.
• W3211250116 cites W2758684245 @default.
• W3211250116 cites W2767394258 @default.
• W3211250116 cites W2770931697 @default.
• W3211250116 cites W2800246801 @default.
• W3211250116 cites W2807791746 @default.
• W3211250116 cites W2808333862 @default.
• W3211250116 cites W2884090647 @default.
• W3211250116 cites W2899259208 @default.
• W3211250116 cites W2923972067 @default.
• W3211250116 cites W2946233321 @default.
• W3211250116 cites W2961111920 @default.
• W3211250116 cites W2965035961 @default.
• W3211250116 cites W2989706656 @default.
• W3211250116 cites W2995742512 @default.
• W3211250116 cites W3006951571 @default.
• W3211250116 cites W3016252363 @default.
• W3211250116 cites W3035163569 @default.
• W3211250116 cites W3048126481 @default.
• W3211250116 cites W3049455588 @default.
• W3211250116 cites W3092992115 @default.
• W3211250116 cites W3105195088 @default.
• W3211250116 cites W3159017730 @default.
• W3211250116 cites W3162970434 @default.
• W3211250116 doi "https://doi.org/10.47360/1995-4484-2021-571-577" @default.
• W3211250116 hasPublicationYear "2021" @default.
• W3211250116 type Work @default.
• W3211250116 sameAs 3211250116 @default.
• W3211250116 citedByCount "1" @default.
• W3211250116 countsByYear W32112501162022 @default.
• W3211250116 crossrefType "journal-article" @default.
• W3211250116 hasAuthorship W3211250116A5002259667 @default.
• W3211250116 hasAuthorship W3211250116A5004963520 @default.
• W3211250116 hasAuthorship W3211250116A5005658823 @default.
• W3211250116 hasAuthorship W3211250116A5039980536 @default.
• W3211250116 hasAuthorship W3211250116A5041569976 @default.
• W3211250116 hasAuthorship W3211250116A5045228828 @default.
• W3211250116 hasAuthorship W3211250116A5063881785 @default.
• W3211250116 hasAuthorship W3211250116A5069106726 @default.
• W3211250116 hasAuthorship W3211250116A5074452337 @default.
• W3211250116 hasAuthorship W3211250116A5086694399 @default.
• W3211250116 hasAuthorship W3211250116A5089450492 @default.
• W3211250116 hasBestOaLocation W32112501161 @default.
• W3211250116 hasConcept C118552586 @default.
• W3211250116 hasConcept C126322002 @default.
• W3211250116 hasConcept C14184104 @default.
• W3211250116 hasConcept C159110408 @default.
• W3211250116 hasConcept C1862650 @default.
• W3211250116 hasConcept C197934379 @default.
• W3211250116 hasConcept C2777575956 @default.
• W3211250116 hasConcept C2778375690 @default.
• W3211250116 hasConcept C2778739829 @default.
• W3211250116 hasConcept C2779134260 @default.
• W3211250116 hasConcept C2779951463 @default.
• W3211250116 hasConcept C535046627 @default.
• W3211250116 hasConcept C558461103 @default.
• W3211250116 hasConcept C71924100 @default.
• W3211250116 hasConceptScore W3211250116C118552586 @default.
• W3211250116 hasConceptScore W3211250116C126322002 @default.
• W3211250116 hasConceptScore W3211250116C14184104 @default.
• W3211250116 hasConceptScore W3211250116C159110408 @default.
• W3211250116 hasConceptScore W3211250116C1862650 @default.
• W3211250116 hasConceptScore W3211250116C197934379 @default.
• W3211250116 hasConceptScore W3211250116C2777575956 @default.
• W3211250116 hasConceptScore W3211250116C2778375690 @default.
• W3211250116 hasConceptScore W3211250116C2778739829 @default.
• W3211250116 hasConceptScore W3211250116C2779134260 @default.
• W3211250116 hasConceptScore W3211250116C2779951463 @default.
• W3211250116 hasConceptScore W3211250116C535046627 @default.
• W3211250116 hasConceptScore W3211250116C558461103 @default.
• W3211250116 hasConceptScore W3211250116C71924100 @default.
• W3211250116 hasIssue "5" @default.
• W3211250116 hasLocation W32112501161 @default.
• W3211250116 hasLocation W32112501162 @default.
• W3211250116 hasOpenAccess W3211250116 @default.
• W3211250116 hasPrimaryLocation W32112501161 @default.

• next